IL17A and arthritic joint disease: Moreover, one report described a patient with severe arthritis after ICI treatment that was controlled by IL‐6 receptor antibody (tocilizumab) treatment.34 However, the effectiveness of other biological agents such as IL‐17 and IL‐12/23 antagonists are still under investigation.